Venture capital firm
ARCH Venture Partners portfolio
archventure.comARCH Venture Partners is a venture capital firm based in Chicago, United States, founded in 1986. It has invested in 99 venture-backed companies across 143 funding rounds on VCMC, and led 60 of those rounds. 17 of them were in the last 12 months.
99
Venture-backed companies
in its portfolio on VCMC
143
Funding rounds
led 60
17
Last 12 months
rounds, Oct 2025 to Sep 2026
10
With a disclosed valuation
of 99 companies
$108.4B
Combined value of its private companies
the whole companies, not what ARCH Venture Partners owns
95 private companies ARCH Venture Partners has backed have a VCMC valuation; together they are worth $108.4B. That is the value of the whole companies, not what ARCH Venture Partners owns. Xaira Therapeutics is 14% of the total. 4 companies it backed have since been acquired and are not included. How VCMC values companies.
Values cover private companies only; public companies are not included.
Portfolio
ARCH Venture Partners' most valuable portfolio companies
The 10 most valuable private companies ARCH Venture Partners has backed, by VCMC's valuation. Values cover private companies only; public companies are not included.
- 1 Xaira Therapeutics Biotechnology, South San Francisco $15.2B range $4.9B – $23.1B Led at Growth, 2024
- 2 Colossal Biotechnology, Austin $14.4B range $8.6B – $16.6B Joined at Series A, 2022
- 3 Aledade Health Care Services, Bethesda $4.1B range $1.2B – $5.6B Led at Series B, 2015
- 4 Encoded Therapeutics Biotechnology, South San Francisco $3.6B range $2.3B – $6.8B Joined at Series C, 2019
- 5 Altos Labs Biotechnology, Redwood City $3.4B range $371M – $7.4B Joined at Series B, 2022
- 6 eGenesis Biotechnology, Cambridge $3.3B range $1.3B – $5.1B Led at Series A, 2017
- 7 Resilience Pharmaceutical Products, Blue Ash $3.3B range $633M – $13.0B Led at Series B, 2020
- 8 Medical Supply Manufacturers, New York $3.2B range $1.7B – $4.5B Led at Series C, 2022
- 9 CuspAI Research Institutes $2.9B range $2.3B – $4.5B Joined at Series A, 2025
- 10 Mirador Biotechnology, San Diego $2.8B range $1.2B – $4.3B Led at Series A, 2024
Portfolio
Full ARCH Venture Partners portfolio (99 companies)
99 companies. Load more shows the rest.
| # | Last round | History | Range | Trend | Grade | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Resilience Pharmaceutical Products · led at Series B, 2020 | Series D Jun 2022 $625M | $3.3B | $633M – $13.0B | $2.8B (-13%) | $1.1B | 59% | 1,307 | flat | D | |
| 2 | Aledade Health Care Services · led at Series B, 2015 | Debt Dec 2025 $500M | $4.1B | $1.2B – $5.6B | $3.9B (-4%) | $548M | 0% | 1,955 | up | C | |
| 3 | Xaira Therapeutics Biotechnology · led at Growth, 2024 | Growth Equity Apr 2024 $1.00B | $15.2B | $4.9B – $23.1B | $9.1B (-40%) | $1.4B | 0% | 212 | up | C | |
| 4 | Altos Labs Biotechnology · since Series B, 2022 | Series B Jan 2022 $800M | $3.4B | $371M – $7.4B | $3.1B (-7%) | $928M | 23% | 549 | flat | D | |
| 5 | Mirador Biotechnology · led at Series A, 2024 | Series B Sep 2025 $250M | $2.8B | $1.2B – $4.3B | $2.8B (0%) | $307M | 0% | 97 | up | C | |
| 6 | Arsenal Bio Biotechnology · led at Series C, 2024 | Series C Sep 2024 $325M | $1.6B | $918M – $3.4B | $826M (-47%) | $368M | 97% | 168 | shrinking | C | |
| 7 | LifeMine Biotechnology · since Series A, 2017 | Series E Aug 2026 $263M | $2.0B | $1.4B – $2.9B | $1.9B (-8%) | $288M | 97% | 32 | shrinking | B | |
| 8 | CuspAI Research Institutes · since Series A, 2025 | Series B Jul 2026 $450M | $2.9B | $2.3B – $4.5B | $3.9B (+35%) | $429M | 0% | 94 | growing | B | |
| 9 | insitro Biotechnology · since Series B, 2020 | Series C Mar 2021 $400M | $1.1B | $195M – $5.8B | $1.0B (-10%) | $497M | 59% | 257 | flat | D | |
| 10 | Encoded Therapeutics Biotechnology · since Series C, 2019 | Series F Sep 2026 $275M | $3.6B | $2.3B – $6.8B | $4.5B (+26%) | $492M | 0% | 192 | up | B | |
| 11 | eGenesis Biotechnology · led at Series A, 2017 | Series D Sep 2024 $191M | $3.3B | $1.3B – $5.1B | $2.3B (-30%) | $368M | 0% | 154 | up | C | |
| 12 | Ollin Biosciences Pharmaceutical Products · led at Series A, 2025 | Series B Jun 2026 $330M | $2.0B | $1.2B – $3.6B | $2.6B (+31%) | $283M | 0% | 28 | unknown | B | |
| 13 | Colossal Biotechnology · since Series A, 2022 | Series C Jan 2025 $200M | $14.4B | $8.6B – $16.6B | $14.4B (0%) | $1.6B | 0% | 266 | up | B | |
| 14 | Tech Companies · led at Seed, 2026 | Seed Jun 2026 $107M | $904M | $479M – $2.2B | $1.5B (+61%) | $262M | 0% | 74 | growing | C | |
| 15 | Hobby Shops · since Series B, 2021 | Series B Nov 2021 $75M | $350M | $30.3M – $511M | $335M (-4%) | $53.6M | 0% | 183 | up | D | |
| 16 | Tech Companies · since Series C, 2025 | Acquisition Jun 2026 $3.92B | $2.0B acquired 2026 | $1.4B – $2.5B | – | – | 0% | 373 | growing | A | |
| 17 | Biotechnology · led at Seed, 2019 | Series C Nov 2025 $115M | $1.4B | $706M – $2.1B | $1.4B (+1%) | $154M | 0% | 139 | up | B | |
| 18 | Biotechnology · since Series A, 2025 | Series B Oct 2026 $135M | $976M | $634M – $2.2B | $1.4B (+48%) | $159M | 0% | 95 | growing | C | |
| 19 | Medical Supply Manufacturers · led at Series C, 2022 | Series D Nov 2025 $200M | $3.2B | $1.7B – $4.5B | $3.2B (+1%) | $352M | 0% | 131 | flat | B | |
| 20 | Automobile Dealers & Manufacturers · since Series A, 2023 | Series C Nov 2025 $160M | $1.8B | $1.0B – $2.7B | $1.9B (+2%) | $206M | 0% | 438 | growing | B | |
| 21 | Pharmaceutical Products · since Series A, 2020 | Growth Equity Jun 2026 $100M | $1.1B | $749M – $1.5B | $949M (-11%) | $105M | 97% | 51 | down | B | |
| 22 | Biotechnology · since Series A, 2020 | Series B Aug 2021 $265M | $190M | $101M – $608M | $184M (-3%) | $281M | 97% | 62 | shrinking | C | |
| 23 | Biotechnology · led at Series A, 2017 | Series C Mar 2025 $74M | $658M | $300M – $1.2B | $540M (-18%) | $93.7M | 62% | 102 | down | C | |
| 24 | Biotechnology · led at Series B, 2020 | Series C Feb 2022 $150M | $126M | $60.5M – $561M | $119M (-5%) | $145M | 97% | 57 | shrinking | D | |
| 25 | Biotechnology · led at Series A, 2023 | Series A Apr 2023 $270M | $380M | $196M – $997M | $228M (-40%) | $337M | 97% | 13 | shrinking | C | |
| 26 | Biotechnology · led at Growth, 2023 | Series B Apr 2025 $155M | $1.5B | $663M – $2.1B | $1.5B (0%) | $161M | 0% | 84 | up | B | |
| 27 | Pharmaceutical Products · led at Series B, 2020 | Series C Mar 2022 $168M | $145M | $86.8M – $404M | $129M (-11%) | $125M | 97% | 40 | shrinking | C | |
| 28 | Biotechnology · led at Series A, 2025 | Series A Jul 2025 $216M | $2.2B | $788M – $3.4B | $2.2B (0%) | $311M | 0% | 69 | up | C | |
| 29 | Biotechnology · since Series A, 2023 | Series A Dec 2023 $213M | $11.8M | $0 – $11.8M | $11.8M (0%) | – | 100% | 150 | unknown | dead | |
| 30 | Pharmaceutical Products · led at Series B, 2020 | Series C Jul 2024 $100M | $1.1B | $293M – $1.6B | $742M (-35%) | $126M | 0% | 34 | flat | C | |
| 31 | Biotechnology · since Series B, 2025 | Series B Jan 2025 $97M | $477M | $268M – $1.0B | $298M (-37%) | $105M | 97% | 40 | shrinking | C | |
| 32 | Biotechnology · since Series B, 2022 | Series B Aug 2022 $200M | $1.7B | $445M – $4.1B | $1.7B (-1%) | $307M | 5% | 70 | growing | D | |
| 33 | Biotechnology · led at Growth, 2025 | Growth Equity Jan 2025 $200M | $2.4B | $1.4B – $3.7B | $2.4B (0%) | $220M | 0% | 53 | growing | B | |
| 34 | Biotechnology · since Series A, 2025 | Series A Mar 2025 $200M | $1.7B | $630M – $2.7B | $1.5B (-11%) | $281M | 27% | 174 | up | C | |
| 35 | Biotechnology · led at Series A, 2023 | Series B May 2026 $122M | $1.0B | $614M – $1.9B | $1.3B (+25%) | $144M | 0% | 47 | up | B | |
| 36 | Pharmaceutical Products · since Series B, 2021 | Series C Jan 2026 $50M | $396M | $258M – $603M | $324M (-18%) | $61.3M | 97% | 123 | down | B | |
| 37 | Biotechnology · led at Series A, 2023 | Series A Feb 2023 $193M | $1.4B | $158M – $3.2B | $1.4B (-6%) | $306M | 0% | 93 | up | D | |
| 38 | Health Care Services · led at Series B, 2022 | Series E Aug 2026 $116M | $1.5B | $953M – $2.6B | $1.7B (+14%) | $207M | 31% | 179 | down | B | |
| 39 | Biotechnology · led at Series A, 2020 | Series E Jan 2026 $48M | $654M | $383M – $1.0B | $610M (-7%) | $83.3M | 46% | 145 | up | B | |
| 40 | Biotechnology · since Series A, 2024 | Growth Equity Nov 2025 $112M | $1.1B | $691M – $1.5B | $1.1B (+1%) | $97.1M | 0% | 25 | up | B | |
| 41 | Tech Companies · since Series B, 2020 | Acquisition May 2026 $475M | $1.1B acquired 2026 | $370M – $1.9B | – | – | 24% | 188 | flat | C | |
| 42 | Biotechnology · led at Series A, 2019 | Series B May 2021 $67M | $283M | $35.5M – $738M | $261M (-8%) | $83.2M | 39% | 25 | flat | D | |
| 43 | Pharmaceutical Products · led at Series A, 2020 | Growth Equity Dec 2025 $53M | $649M | $395M – $1.0B | $640M (-1%) | $59.6M | 8% | 32 | flat | B | |
| 44 | Biotechnology · since Growth, 2017 | Series C Sep 2018 $80M | $101M | $54.3M – $292M | $101M (0%) | $122M | 97% | 53 | shrinking | C | |
| 45 | Biotechnology · since Seed, 2025 | Seed May 2025 $155M | $2.1B | $574M – $3.1B | $2.1B (0%) | $372M | 0% | 44 | up | C | |
| 46 | Pharmaceutical Products · led at Series A, 2016 | Series D Dec 2022 $35M | $194M | $30.3M – $595M | $159M (-18%) | $48.9M | 33% | 16 | flat | D | |
| 47 | Biotechnology · led at Series A, 2021 | Series A Aug 2021 $150M | $652M | $25.7M – $2.0B | $649M (0%) | $210M | 4% | 28 | unknown | D | |
| 48 | Biotechnology · since Series B, 2021 | Series B Apr 2021 $139M | $629M | $58.2M – $1.9B | $605M (-4%) | $164M | 20% | 47 | up | D | |
| 49 | Pharmaceutical Products · led at Series B, 2026 | Series B Mar 2026 $120M | $846M | $467M – $1.4B | $994M (+17%) | $109M | 0% | 17 | unknown | B | |
| 50 | Biotechnology · since Series B, 2023 | Series B Mar 2023 $135M | $82.8M | $54.7M – $181M | $45.3M (-45%) | $50.9M | 97% | 13 | shrinking | B |
Valuation: VCMC's valuation with its range, from a low to a high scenario; a company with no valuation shows a dash, one acquired after its last round its last value as a private company.
Activity
How ARCH Venture Partners invests: stages, industries and countries
Most of its rounds are Series A (37%). Its companies span 16 industries, most in Biotechnology, Pharmaceutical Products and Medical Supply Manufacturers, across 7 countries.
Rounds by stage
- Seed 8
- Series A 53
- Series B 41
- Series C and later 41
Investments by industry
- Biotechnology 59
- Pharmaceutical Products 13
- Medical Supply Manufacturers 5
- Tech Companies 4
- Health Care Services 3
- Laboratory Equipment & Supplies 3
- Home Health Care 2
- Medical Laboratories 2
Investments by country
- United States 88
- United Kingdom 5
- China 2
- Germany 1
- Singapore 1
- Sweden 1
Recent rounds
ARCH Venture Partners' latest investments
ARCH Venture Partners' most recent funding rounds, newest first. 17 rounds in the last 12 months.
- Series B $135M 13 Oct 2026
- Encoded Therapeutics Series F $275M 9 Sep 2026
- Series B $70M 9 Sep 2026
- LifeMine Series E $263M 7 Aug 2026
- Seed, led $107M 25 Jun 2026
- Ollin Biosciences Series B, led $330M 24 Jun 2026
- Growth, led $26M 28 May 2026
- Series B, led $122M 14 May 2026
- Series B, led $120M 18 Mar 2026
- Series A, led $80M 26 Feb 2026
Co-investors
ARCH Venture Partners' top co-investors
The investors that most often join the same rounds as ARCH Venture Partners. GV leads, with 29 rounds together.
- GV 29 rounds together
- Invus 14 rounds together
- 12 rounds together
- 11 rounds together
- 10 rounds together
- General Catalyst 10 rounds together
- 9 rounds together
- Andreessen Horowitz 9 rounds together
- 9 rounds together
- Lux Capital 9 rounds together
About
About ARCH Venture Partners
ARCH Venture Management LLC, known as ARCH Venture Partners, is an American venture capital firm that provides seed and early-stage investments in technology, life sciences, and physical sciences. The company supports the development of biotechnology, semiconductors, and technology companies, and facilitates strategic partnerships and collaborations to advance research and development in the life sciences sector.
Description from Veridion's company data.
- Founded
- 1986
- Based in
- Chicago, United States
- Team
- 66 people, +20% in a year
- Type
- Venture capital firm
Focus markets
- Technology
- Life Sciences
- Physical Sciences
What ARCH Venture Partners offers
- Venture Capital Investment Services
- Technology Sector Investment Services
- Biotechnology Investment Services
- Life Sciences Investment Services
- Physical Sciences Investment Services
- Seed and Early-Stage Investment Services
- Disruptive Company Development Services
- Portfolio Company Growth Services
Questions
ARCH Venture Partners: frequently asked questions
How many companies has ARCH Venture Partners invested in?
99 venture-backed companies on VCMC, across 143 funding rounds.
What are ARCH Venture Partners' most valuable private companies?
Xaira Therapeutics ($15.2B), Colossal ($14.4B), Aledade ($4.1B), by VCMC's valuation.
What was ARCH Venture Partners' latest investment?
Soufflé Therapeutics, a Series B round in Oct 2026 of $135M.
Which stages does ARCH Venture Partners invest in?
ARCH Venture Partners invests most often at Series A (53 rounds), followed by Series B (41) and Series C and later (41). It has also joined 8 seed rounds.
What is ARCH Venture Partners' portfolio worth?
Its private companies with a VCMC valuation are worth $108.4B together. That is the sum of the companies' values, not what ARCH Venture Partners owns.
Who does ARCH Venture Partners invest alongside?
GV (29 rounds), Invus (14 rounds), F-Prime Capital (12 rounds).